Lisa Williams
Psychiatric/Mental Health · Memphis, TNNPI 1376658062
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 404 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 30.7% of the total. Among psychiatric/mental health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 404 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Takeda Pharmaceuticals U.S.A., Inc.$993
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$717
- Teva Pharmaceuticals USA, Inc.$573
- Johnson & Johnson$528
- Axsome Therapeutics, Inc.$376
- plus $3K from 21 others
What the payments were for
- Consulting fees$1151%
- Food & beverage$8,05797%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 154 | $2,545 |
| Takeda Pharmaceuticals U.S.A., Inc. | 62 | $993 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $717 |
| Teva Pharmaceuticals USA, Inc. | 16 | $573 |
| Johnson & Johnson | 20 | $528 |
| Axsome Therapeutics, Inc. | 19 | $376 |
| Alkermes, Inc. | 16 | $336 |
| Lundbeck LLC | 16 | $312 |
| Tris Pharma Inc | 10 | $251 |
| Regeneron Healthcare Solutions, Inc. | 2 | $246 |
| Neurocrine Biosciences, Inc. | 11 | $212 |
| Bausch Health US, LLC | 9 | $174 |
| Supernus Pharmaceuticals, Inc. | 8 | $144 |
| E.r. Squibb & Sons, L.L.C. | 2 | $144 |
| Otsuka America Pharmaceutical, Inc. | 6 | $119 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Idorsia Pharmaceuticals US Inc | 1 | $111 |
| Sunovion Pharmaceuticals Inc. | 6 | $91 |
| Corium, LLC | 4 | $71 |
| Novo Nordisk | 2 | $41 |
| Lilly USA, LLC | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Eisai Inc. | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Adlon Therapeutics L.p. | 1 | $22 |
| OWP Pharmaceuticals, Inc. | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$240
- VRAYLAR$223
- EYLEA HD$130
- Dyanavel XR$124
- Quillivant$124
- Quillichew ER$124
- COBENFY$123
- Austedo XR$119
- EYLEA$117
- QUVIVIQ$111
- AUSTEDO$103
How this compares
$8,284 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $105,774 |
| AustedoDeutetrabenazine | 13 | $98,181 |
| Lurasidone Hcl | 16 | $3,233 |
| Bupropion XlBupropion Hcl | 50 | $1,681 |
| Vilazodone Hcl | 14 | $1,534 |
| Lamotrigine | 65 | $1,287 |
| Olanzapine | 16 | $1,214 |
| Buspirone Hcl | 48 | $1,118 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $874 |
| Sertraline Hcl | 54 | $697 |
| Temazepam | 23 | $686 |
| Fluoxetine Hcl | 75 | $649 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 38 | $644 |
| Fluvoxamine Maleate | 15 | $623 |
| Duloxetine Hcl | 30 | $585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $212 | $105,77414 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $573 | $98,18113 claims |
| Lilly USA, LLCOlanzapine | $37 | $1,21416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Memphis
- Mary AllenMemphis$422K
- Sarah VogelfangerMemphis$94K
- Michael HobbsMemphis$23K
- Angela HammondMemphis$16K
- Kristen LockeMemphis$9K
- Latasha GarrettMemphis$8K
- Kristin FitchpatricMemphis$8K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.